The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index; 3 of the 7 sources its claims cite were checked for support.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Open accessAbstract
BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known. METHODS: We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the pooled empagliflozin group versus the placebo group. The key secondary composite outcome was the primary outcome plus hospitalization for unstable angina. RESULTS: A total of 7020 patients were treated (median observation time, 3.1 years). The primary outcome occurred in 490 of 4687 patients (10.5%) in the pooled empagliflozin group and in 282 of 2333 patients (12.1%) in the placebo group (hazard ratio in the empagliflozin group, 0.86; 95.02% confidence interval, 0.74 to 0.99; P=0.04 for superiority). There were no significant between-group differences in the rates of myocardial infarction or stroke, but in the empagliflozin group there were significantly lower rates of death from cardiovascular causes (3.7%, vs. 5.9% in the placebo group; 38% relative risk reduction), hospitalization for heart failure (2.7% and 4.1%, respectively; 35% relative risk reduction), and death from any cause (5.7% and 8.3%, respectively; 32% relative risk reduction). There was no significant between-group difference in the key secondary outcome (P=0.08 for superiority). Among patients receiving empagliflozin, there was an increased rate of genital infection but no increase in other adverse events. CONCLUSIONS: Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care. (Funded by Boehringer Ingelheim and Eli Lilly; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
3 of 7 cited sources checked · 2 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Evidence that glucose lowering reduces the rates of cardiovascular events and death has not been convincingly shown, 4-6”
What the sources say
- Partly supportedcites [4] sourceExperimental — accuracy not yet measured
The Results (p. 1) report that sitagliptin lowered glycated hemoglobin but did not reduce the primary cardiovascular outcome; Other Secondary Outcomes (p. 4) show no reduction in death from any cause. These findings support the lack of a demonstrated benefit for sitagliptin in this trial, but do not establish the broader claim about glucose lowering generally. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [5] source
- Supportedcites [6] source
The paper says uncertainty remains about whether glucose-lowering strategies can reduce cardiovascular risk; it notes that most trials had not shown a significant cardiovascular benefit, while acknowledging possible exceptions for metformin and insulin. The Discussion likewise says that whether improved glycemic control reduces macrovascular events remains in question. Its reported death outcomes do not show a significant reduction. (LLM, conf=0.90)
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Fatal or nonfatal stroke | 69 (3.0) | 10.5 | 164 (3.5) | 12.3 | 1.18 (”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“P<0.001 for noninferiority”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A sensitivity analysis of death from any cause in which it was assumed that all patients who were lost to follow-up in the empagliflozin group died and all patients who were lost to follow-up in the placebo group were alive showed a significant benefit of empagliflozin versus placebo (hazard ratio, 0.77; 95% CI, 0.65 to 0.93; P = 0.005).”
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- The authors state this as an assumption: In the sensitivity analysis of death from any cause, all patients lost to follow-up in the empagliflozin group were assumed to have died and all patients lost to follow-up in the placebo group were assumed to be alive.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In subgroup analyses, there was some heterogeneity for the primary outcome.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no significant between-group difference in the key secondary outcome (P = 0.08 for superiority).”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no relevant changes in electrolytes in the two study groups.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All categories of death from cardiovascular causes contributed to the reduction in cardiovascular death in the empagliflozin group”
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients with type 2 diabetes at high risk for cardiovascular events, those receiving empagliflozin had a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke than did patients receiving placebo.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with no significant between-group difference in the risk of myocardial infarction or stroke.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 16
- The quote only partly states this claim. 4
- It may state two separate claims as one. 20
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inhibitors of sodium-glucose cotransporter 2 reduce rates of hyperglycemia in patients with type 2 diabetes by decreasing renal glucose reabsorption, thereby increasing urinary glucose excretion. 10”
What the sources say
- Supportedcites [10] source
The Introduction states that SGLT2 inhibitors block renal glucose reabsorption, increase urinary glucose excretion, and have anti-hyperglycaemic effects. The Conclusion also states that SGLT2 inhibition lowers renal glucose reabsorption and blood glucose levels and may be effective in type 2 diabetes. (LLM, conf=0.93)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Genital infection was reported in a higher percentage of patients in the pooled empagliflozin group.”
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A higher percentage of patients in the placebo group received additional glucose-lowering medications (including sulfonylurea and insulin), antihypertensive medications (including diuretics), and anticoagulants during the trial, with no between-group difference in the receipt of lipidlowering drugs”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Over the course of the study, empagliflozin, as compared with placebo, was associated with small reductions in weight, waist circumference, uric acid level, and systolic and diastolic blood pressure with no increase in heart rate and small increases in both LDL and HDL cholesterol”
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“at week 206, the differences were -0.24 percentage points (95% CI, -0.40 to -0.08) and -0.36 percentage points (95% CI, -0.51 to -0.20).”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Myocardial infarction was reported in 4.8% of patients in the empagliflozin group and 5.4% of those in the placebo group, and stroke in 3.5% and 3.0% of patients, respectively.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Urosepsis was reported in 0.4% of patients in the empagliflozin group and 0.1% of those in the placebo group, but there was no imbalance in overall rates of urinary tract infection, complicated urinary tract infection, or pyelonephritis”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“After 12 weeks, during which glucose-lowering therapy was to remain unchanged, the adjusted mean differences in the glycated hemoglobin level between patients receiving empagliflozin and those receiving placebo were -0.54 percentage points (95% CI, -0.58 to -0.49) in the 10-mg group and -0.60 percentage points (95% CI, -0.64 to -0.55) in the 25-mg group”
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“death from any cause (5.7% and 8.3%, respectively; 32% relative risk reduction)”
- Also stated in: § CONCLUSIONS · p. 1 · plain
“Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascular outcome and of death from any cause when the study drug was added to standard care.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
- Also stated in: § CONCLUSIONS · p. 1 · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportions of patients who had adverse events, serious adverse events, and adverse events leading to the discontinuation of a study drug were similar in the empagliflozin group and the placebo group”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportions of patients with diabetic ketoacidosis, volume depletion, thromboembolic events, and bone fracture were low (ranging from <1% for ketoacidosis and thromboembolic events to 5% for volume depletion) and similar in the empagliflozin groups and the placebo group.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among patients receiving empagliflozin, there was an increased rate of genital infection but no increase in other adverse events.”
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no significant between-group differences in the rates of myocardial infarction or stroke”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in the empagliflozin group there were significantly lower rates of death from cardiovascular causes (3.7%, vs. 5.9% in the placebo group; 38% relative risk reduction)”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hematocrit values were higher in the empagliflozin groups than in the placebo group”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The proportions of patients with confirmed hypoglycemic adverse events, acute renal failure, diabetic ketoacidosis, thromboembolic events, bone fracture, and events consistent with volume depletion were similar in the two study groups.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the percentage of patients with acute renal failure (including acute kidney injury) was lower in the empagliflozin groups than in the placebo group, and renal function was maintained with empagliflozin.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hazard ratios for the primary outcome were 0.85 (95% CI, 0.72 to 1.01; P = 0.07) for the 10-mg dose of empagliflozin versus placebo and 0.86 (95% CI, 0.73 to 1.02; P = 0.09) for the 25-mg dose versus placebo.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“hospitalization for heart failure (2.7% and 4.1%, respectively; 35% relative risk reduction)”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and the point estimate for the hazard ratio for stroke was closer to 1.00”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For the primary and key secondary outcomes, hazard ratios for the comparison between the 10-mg dose of empagliflozin versus placebo and the 25-mg dose versus placebo were virtually identical to those in the pooled analysis, but the individual dose effects were not significant”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“there is concern that intensive glucose lowering or the use of specific glucose-lowering drugs may be associated with adverse cardiovascular outcomes. 8”
What the sources say
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Empagliflozin is a selective inhibitor of sodium glucose cotransporter 2 11”
What the sources say
- Not checked — no full text of the sourcecites [11] source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Randomization was performed with the use of a computer-generated random-sequence and interactive voice- and Web-response system and was stratified according to the glycated hemoglobin level at screening (<8.5% or ≥8.5%), bodymass index at randomization (<30 or ≥30), renal function at screening (eGFR, 30 to 59 ml, 60 to 89 ml, or ≥90 ml per minute per 1.73 m 2 ), and geographic region”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We performed the primary analysis using a modified intention-to-treat approach among patients who had received at least one dose of a study drug.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but these numbers cannot be extrapolated to patient populations with other clinical characteristics.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it.
In the paper
“Cardiovascular outcome events and deaths were prospectively adjudicated by two clinical-events committees (one for cardiac events and the other for neurologic events), as recommended by the Food and Drug Administration (FDA) guidelines. 9”
What the sources say
- Not matchedcites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of treatment was 2.6 years, and the median observation time was 3.1 years; both durations were similar in the pooled empagliflozin group and the placebo group”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Members of the University of Freiburg conducted an independent statistical analysis of cardiovascular outcomes”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial was conducted in accordance with the principles of the Declaration of Helsinki and the the International Conference on Harmonisation Good Clinical Practice guidelines and was approved by local authorities. An independent ethics committee or institutional review board approved the clinical protocol at each participating center.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“this was a randomized, double-blind, placebo-controlled trial”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our trial provides data to support the longterm use of empagliflozin, as well as strong evidence for a reduction in cardiovascular risk.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, 97.0% of patients completed the study, with 25.4% of patients prematurely discontinuing a study drug. Final vital status was available for 99.2% of patients.”
Strength:plain· not yet calibratedn = 7,028Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Safety data were reviewed by an independent academic data monitoring committee every 90 days or at the discretion of the committee.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The trial continued until an adjudicated primary outcome event had occurred in at least 691 patients.”
Strength:plain· not yet calibratedn = 691Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Analyses were based on a Cox proportional-hazards model, with study group, age, sex, baseline body-mass index, baseline glycated hemoglobin level, baseline eGFR, and geographic region as factors.”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
The paper relies on this without support.
The effects of empagliflozin, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk were not known before this trial.
“The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.”
The authors state this as an assumption.
In the sensitivity analysis of death from any cause, all patients lost to follow-up in the empagliflozin group were assumed to have died and all patients lost to follow-up in the placebo group were assumed to be alive.
“A sensitivity analysis of death from any cause in which it was assumed that all patients who were lost to follow-up in the empagliflozin group died and all patients who were lost to follow-up in the placebo group were alive”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“and the risk of reduction in eGFR, ESKD, or death from ESKD by 40%”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“It is important to note that Black Americans were underrepresented in this trial comprising only 3.3% of all participants and that this trend towards greater amputations was not found in subsequent analyses.”
From Racial and Ethnic Disparities in Peripheral Artery Disease (2021) · cites this paper as [94]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The time to benefit emerged earlier in that trial than in the present trial”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In recent years, sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor antagonists (GLP-1RAs) have demonstrated benefits in preventing deleterious cardiorenal endpoints among individuals with type 2 diabetes, shifting disease management from a glucocentric approach to one that prioritises long-term cardiorenal health [5–7].”
From Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013–2019 (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and the risk of doubling of serum creatinine accompanied by eGFR #45 mL/min/1.73m 2 by 44%”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is substantial evidence con fi rming that SGLT2i confer signi fi cant kidney and heart protective effects in these patients.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As discussed, there have now been 4 RCTs 87,89,90,93 and a meta-analysis of 4 of these trials 97 that have con fi rmed the signi fi cant bene fi ts of SGLT2i on clinically meaningful kidney outcomes beyond just proteinuria as a surrogate marker.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recommendation is strong due to the known kidney and/or cardiovascular protective effects in patients with T2D and CKD as shown in high-quality trials, such as EMPA-REG, CANVAS, DECLARE-TIMI 58, CREDENCE, DAPA-CKD, SCORED, DAPA-HF, SOLOIST, EMPEROR-Reduced and EMPEROR-Preserved.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The similar rates of amputation and fracture that we observed with canagliflozin and placebo are reassuring and consistent with trials of other SGLT2 inhibitors 6,7,20 but differ from the CANVAS Program findings.5”
From Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (2019) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [255]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EMPA-REG OUTCOME trial, only 10% of study participants had a prior history of heart failure, and treatment with empagliflozin reduced the relative risk for hospitalization from heart failure by 35% (281).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [281]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large clinical trials have shown benefits of newer glucose-lowering medications on cardiovascular and kidney outcomes in patients with CKD with type 2 diabetes.5, 6, 7, 8, 9, 10, 11, 12, 13, 14”
From Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States (2023) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stratified analyses of the trials of this drug class indicate that older adults have similar or greater benefits than younger people (116-118).”
From 13. Older Adults: Standards of Care in Diabetes—2024 (2024) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Stratified analyses of the trials of this drug class indicate that older adults have similar or greater benefits than younger people”
From 13. Older Adults: Standards of Care in Diabetes—2026 (2026) · cites this paper as [139]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Clinical trials of other SGLT2 inhibitors have shown similar results.8,10,19”
From Dapagliflozin in Patients with Chronic Kidney Disease (2020) · cites this paper as [19]
The cited source says what the claim attributes to it.
In the citing paper
“The pattern of cardiovascular benefits that were associated with liraglutide in our trial appears to differ from that with the sodium–glucose cotransporter 2 inhibitor empagliflozin in the previously reported EMPA-REG OUTCOME trial.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“the heterogeneity of the direction and magnitude of the effects on the components of the primary composite outcome in that trial contrasts with the consistency of the effect in the present trial.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
The cited source says what the claim attributes to it.
In the citing paper
“Pharmaceutical interventions of 1.5 to 3 years duration report HbA1c reductions of 0.2 to 1.0% with DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 agonists (6, 7, 49).”
The cited source says what the claim attributes to it.
In the citing paper
“Participants with T2D and an eGFR as low as 30 ml/min per 1.73 m 2 were included in the EMPA-REG, CANVAS, and CREDENCE trials, 87,90,93 and ef fi cacy and safety in these studies were consistent across both eGFR and albuminuria down to this threshold.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [90]
The cited source says what the claim attributes to it.
In the citing paper
“The EMPA-REG OUTCOME trial also showed that empagliflozin was superior to placebo, 6”
From Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (2019) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Recently, trials evaluating a sodium-glucose cotransporter 2 inhibitor (empagliflozin) and a glucagon-like peptide 1 (GLP-1) analogue (liraglutide) have shown improved cardiovascular outcomes in patients with type 2 diabetes who were at high risk for cardiovascular events.2,3”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“To date, two antihyperglycemic agents have been shown to reduce the rate of cardiovascular events in patients with type 2 diabetes at high cardiovascular risk.2,3”
From Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“The BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) showed that treatment with empagliflozin reduced the composite outcome of MI, stroke, and cardiovascular death by 14% (absolute rate 10.5% vs. 12.1% in the placebo group, HR in the empagliflozin group 0.86 [95% CI 0.74-0.99];P = 0.04 for superiority) and cardiovascular death by 3”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [255]
The cited source says what the claim attributes to it.
In the citing paper
“In the EMPA-REG OUTCOME trial, only 10% of study participants had a prior history of heart failure, and treatment with empagliflozin reduced the relative risk for hospitalization from heart failure by 35% (255).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [255]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Specifically, compared with placebo, empagliflozin reduced the risk of incident or worsening nephropathy (a composite of progression to UACR >300 mg/g creatinine, doubling of serum creatinine, ESKD, or death from ESKD) by 39%”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“canagliflozin reduced the risk of progression of albuminuria by 27%”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“and semaglutide reduced the risk of new or worsening nephropathy (a composite of persistent UACR >300 mg/g creatinine, doubling of serum creatinine, or ESKD) by 36% (each P < 0.01).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“liraglutide reduced the risk of new or worsening nephropathy (a composite of persistent macroalbuminuria, doubling of serum creatinine, ESKD, or death from ESKD) by 22%”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [111]
Experimental — accuracy not yet measuredIn the citing paper
“Among patients with type 2 diabetes at high risk for cardiovascular events, SGLT2 inhibitor use has been shown to significantly reduce death from cardiovascular causes and to lower the risk of hospitalization for heart failure and progression of kidney disease.4,6”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [4]
In the citing paper
“Given the additional beneficial effects of GLP-1 RAs and SGLT2 inhibitors on CV outcomes in T2DM (Section 5.3), these agents should be the preferred glucose-lowering medication in overweight and obese patients with CVD and T2DM, as obesity medications have, to date, not shown to reduce CV events.[70][71][72]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [71]
In the citing paper
“Empagliflozin reduced the risk of HF hospitalization by 35% in patients with and without previous HF.71”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [71]
In the citing paper
“SGLT2 inhibitors, compared with placebo, were associated with more new-onset AF cases in EMPA-REG OUTCOME (empagliflozin vs. placebo), but fewer incident AF cases in CANVAS (canagliflozin vs. placebo) and DECLARE-TIMI 58 (dapagliflozin vs. placebo).71,151,153,603”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [71]
In the citing paper
“In the CRIC (Chronic Renal Insufficiency Cohort) study, approximately 40% of participants with established CKD had apparent treatment-resistant hypertension.22”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [22]
In the citing paper
“The pattern of use of BP lowering therapies and prevalence of resistant hypertension in CREDENCE is consistent with these data, and suggest that our findings are likely to be directly applicable to the routine care of patients with T2DM and CKD, where the burden of resistant hypertension and use of multiple BP lowering therapies is high.”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [22]
In the citing paper
“The CVOTs designed to test safety and a CKD trial (CREDENCE) were comparable in key aspects: participants with T2DM, placebo controls, SGLT2 inhibitor dose not based on glycemia, all participants treated by standard of care, and similarly defined and adjudicated outcomes.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [35]
In the citing paper
“After a median follow-up of 3.1 years, patients treated with empagliflozin had a 14% lower relative risk for cardiovascular death, myocardial infarction, or stroke (hazard ratio [HR], 0.86; 95% CI, 0.74–0.99) (35).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [35]
In the citing paper
“Diuresis is an important mechanism for reducing blood pressure and risk for HF events (11–16,35).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [35]
In the citing paper
“The benefit of empagliflozin on the primary CVD composite outcome was largely driven by a significant reduction in CVD death rates (3.7% vs. 5.9%; HR, 0.62 [95% CI, 0.49–0.77]).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [35]
In the citing paper
“cardiovascular event rates remain high, even among the patients with well-managed T2DM enrolled in contemporary outcomes trials,8–10”
In the citing paper
“several cardiovascular outcomes trials (CVOTs) demonstrated that drugs that lowered HbA1c to similar levels had different effects on cardiovascular outcomes”
In the citing paper
“empagliflozin reduced MACEs by 14% (HR, 0.86 [95% CI, 0.75–0.99]) in patients with established cardiovascular disease”
In the citing paper
“which was driven primarily by a significant reduction in cardiovascular mortality (3.7% versus 5.9%; 38% RRR)”
In the citing paper
“Empagliflozin also reduced all-cause mortality (5.7% versus 8.3%; 32% RRR)”
In the citing paper
“Large cardiovascular outcome trials provided initial proof that SGLT2 inhibitors slow the progression of kidney function decline and reduce the risks of kidney outcomes in patients with T2D of whom the majority had relatively preserved kidney function (Wiviott et al., 2019; Neal et al., 2017; Zinman et al., 2015; Mosenzon et al., 2019).”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as Zinman et al., 2015
In the citing paper
“A limitation of our study is that it was started before GLP-1 receptor agonists 24 and SGLT2 inhibitors 25 were shown to reduce major cardiovascular events and mortality in patients with stable cardiovascular disease and type 2 diabetes.”
In the citing paper
“Rates of heart failure hospitalization have been improved in recent trials including people with type 2 diabetes, most of whom also had ASCVD, with sodium -glucose cotransporter 2 (SGLT2) inhibitors (8 -11).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [8]
In the citing paper
“and cardiovascular death by 38% (absolute rate 3.7% vs. 5.9%, HR 0.62 [95% CI 0.49 -0.77]; P < 0.001) (8).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [8]
In the citing paper
“EMPA-REG OUTCOME showed that over a median follow-up of 3.1 years, treatment reduced the composite outcome of MI, stroke, and cardiovascular death by 14% (absolute rate 10.5% vs. 12.1% in the placebo group, HR in the empagli fl ozin group 0.86 [95% CI 0.74 -0.99]; P = 0.04 for superiority)”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [8]
In the citing paper
“In EMPAREG OUTCOME, the addition of empaglifl ozin to standard care led to a signi fi cant 35% reduction in hospitalization for heart failure compared with placebo (8).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [8]
In the citing paper
“Reduced incidence of heart failure has been observed with the use of SGLT2 inhibitors (8,194,196).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [8]
In the citing paper
“However, a longer duration of 8–15 years after strict glycemic control is necessary for the suppression of ASCVD risk797, 798).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [797]
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [20]
In the citing paper
“In the EMPA-REG OUTCOME trial (n=7020), including patients with T2DM, established CV disease and eGFR >30 mL/min/1.73m 2 , there was a major reduction in HF hospitalization (HR 0.65) with empagliflozin compared with placebo.20”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [20]
In the citing paper
“A significant breakthrough in contemporary cardiology was the finding that some T2DM drugs are associated with a lower risk of HF hospitalization in patients with CV disease or at high risk of CV disease (Table 8).”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [20]
In the citing paper
“Two large RCTs that assessed CV safety of the sodium-glucose co-transporter type 2 (SGLT2) inhibitors, empagliflozin and canagliflozin, have shown a significant reduction in HF hospitalization with both drugs.20,189”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [20]
In the citing paper
“Empagliflozin in EMPA-REG OUTCOME, but not canagliflozin in CANVAS, reduced all-cause and CV mortality as well as HF hospitalization.”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [20]
In the citing paper
“Darapladib (which targeted Lp-PLA 2 ) failed in SOLID-TIMI 52 128 and STABILITY 129 trials”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [128]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,765
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Self-citationAssociation of cardiometabolic multimorbidity with mortality
Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., Butterworth, A. S., Bansal, N., O’Keeffe, L. M., Gao, P., Wood, A. M., Burgess, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.7008 · Cited by 1,155
Ronco, C., McCullough, P. A., Anker, S. D., Anand, I. S., Aspromonte, N., Bagshaw, S. M., Bellomo, R., Berl, T., Bobek, I., Cruz, D. N., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp507 · Cited by 1,137
Grempler, R., Thomas, L., Eckhardt, M., Himmelsbach, F., Sauer, A., Sharp, D. E., Bakker, R. A., Mark, M., Klein, T., & Eickelmann, P. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01517.x · Cited by 608
Flagged first, then by citations
Research works printed but not linked: 2
- Rosenstock J, 2015, Diabetes Obes Metab
- Chilton RC, 2014, Diabetes Obes Metab
Cited by
Sorted by citations
Items 2,101–2,200 of 12,150
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata‐Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 60
Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
(2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.02.006 · Cited by 49
Evans, M., Morgan, A. R., Davies, S., Beba, H., & Strain, W. D. (2022) · Age and Ageing · doi:10.1093/ageing/afac201 · Cited by 50
Jain, R., Stone, J. A., Agarwal, G., Andrade, J. G., Bacon, S., BAJAJ, H. S., Baker, B., Cheng, G., Dannenbaum, D. A., Gelfer, M., et al. (2022) · Canadian Medical Association Journal · doi:10.1503/cmaj.220138 · Cited by 50
Treatment of type 2 diabetes patients with heart conditions
Aktaş, G., Tel, B. M. A., Tel, M. R., & Balci, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204941 · Cited by 49
Mitochondrial quality control in cardiac fibrosis: Epigenetic mechanisms and therapeutic strategies
Lin, L.-C., Tu, B., Song, K., Liu, Z., Sun, H., Zhou, Y., Sha, J.-M., Yang, J., Ye, Z., Zhao, J., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155626 · Cited by 52
Ozaki, A. F., Ko, D. T., Chong, A. S., Fang, J., Atzema, C. L., Austin, P. C., Stukel, T. A., Tu, K., Udell, J. A., Naimark, D. M. J., et al. (2023) · CMAJ Open · doi:10.9778/cmajo.20220039 · Cited by 49
Diabetic Ketoacidosis in Children and Adolescents; Diagnostic and Therapeutic Pitfalls
Kostopoulou, E., Sinopidis, X., Fouzas, S., Gkentzi, D., Dassios, T. G., Roupakias, S., & Dimitriou, G. (2023) · Diagnostics · doi:10.3390/diagnostics13152602 · Cited by 74
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors
Mashayekhi, M., Safa, B. I., Gonzalez, M. S. C., Kim, S. F., & Echouffo-Tcheugui, J. B. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.02.003 · Cited by 54
Bone metabolism in diabetes: a clinician’s guide to understanding the bone–glucose interplay
Sheu, A., & White, C. (2024) · Diabetologia · doi:10.1007/s00125-024-06172-x · Cited by 55
SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives
Morciano, C., Gugliandolo, S., Capece, U., Giuseppe, G. D., Mezza, T., Ciccarelli, G., Soldovieri, L., Brunetti, M., Avolio, A., Splendore, A., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02539-x · Cited by 52
Altabas, V., Altabas, K., & Kirigin, L. S. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.02.009 · Cited by 49
Mannucci, E., Mosenzon, O., & Avogaro, A. (2016) · Diabetes Care · doi:10.2337/dcs15-3024 · Cited by 48
Rørth, R., Jhund, P. S., Mogensen, U. M., Kristensen, S. L., Petrie, M. C., Køber, L., & McMurray, J. J. V. (2018) · Diabetes Care · doi:10.2337/dc17-2583 · Cited by 50
Connelly, K. A., Zhang, Y., Desjardins, J., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0741-9 · Cited by 48
Young, J. B., Gauthier‐Loiselle, M., Bailey, R. A., Manceur, A. M., Lefèbvre, P., Greenberg, M., Lafeuille, M., Duh, M. S., Bookhart, B., & Wysham, C. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0759-z · Cited by 48
Takahashi, H., Nomiyama, T., Terawaki, Y., Horikawa, T., Kawanami, T., Hamaguchi, Y., Tanaka, T., Motonaga, R., Fukuda, T., Tanabe, M., et al. (2019) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2019.100640 · Cited by 48
Ritsinger, V., Nyström, T., Saleh, N., Lagerqvist, B., & Norhammar, A. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319901063 · Cited by 50
Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M. G., Disoteo, O., Sommese, C., Fiorina, P., Ambrosio, G., & Folli, F. B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105052 · Cited by 51
Lee, H., Chen, S., Liu, J., Li, P., Wu, L., Chang, S., Yeh, Y., Kuo, C.-T., Chan, Y., & See, L. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01118-0 · Cited by 49
Evans, M., Morgan, A. R., Patel, D., Dhatariya, K., Greenwood, S. A., Newland‐Jones, P., Hicks, D., Yousef, Z. R., Moore, J., Kelly, B., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00963-2 · Cited by 53
Silverii, G. A., Monami, M., & Mannucci, E. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14286 · Cited by 51
Liu, Y., Xu, J., Wu, M., Xu, B., & Kang, L. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01430-y · Cited by 49
Yan, Y., Liu, B., Du, J. C., Wang, J., Jing, X., Liu, Y., Deng, S., Du, J., & She, Q. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13313 · Cited by 48
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
Jeong, S. J., Lee, S. E., Shin, D. H., Park, I. B., Lee, H. S., & Kim, K. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02381-3 · Cited by 49
Xie, Y., Bowe, B. C., Gibson, A. K., McGill, J. B., Maddukuri, G. S., & Al‐Aly, Z. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2488 · Cited by 49
Yu, Y.-W., Zhao, X.-M., Wang, Y.-H., Zhou, Q., Huang, Y., Zhai, M., & Zhang, J. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01209-y · Cited by 48
Lee, S., Zhou, J., Leung, K. S. K., Wai, A. K. C., Jeevaratnam, K., King, E., Liu, T., Wong, W. T., Chang, C., Wong, I. C. K., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07319-x · Cited by 50
Schnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 47
van Bommel, E. J. M., Lytvyn, Y., Perkins, B. A., Soleymanlou, N., Fagan, N. M., Koitka-Weber, A., Joles, J. A., Cherney, D. Z. I., & van Raalte, D. H. (2020) · Kidney International · doi:10.1016/j.kint.2019.12.021 · Cited by 47
Fernández‐Fernández, B., Fernández-Prado, R., Górriz, J. L., Martínez‐Castelao, A., Navarro‐González, J. F., Porrini, E., Soler, M. J., & Ortíz, A. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz070 · Cited by 48
Anderson, J. E. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0031 · Cited by 49
Thein, D., Christiansen, M. N., Mogensen, U. M., Bundgaard, J. S., Rørth, R., Madelaire, C., Fosbøl, E. L., Schou, M., Torp-Pedersen, C. T., Gislason, G., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01078-5 · Cited by 48
Kosiborod, M., Berwanger, O. B., Koch, G. G., Martínez, F. A., Mukhtar, O., Verma, S., Chopra, V., Javaheri, A., Ambery, P., Gasparyan, S. B., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14296 · Cited by 48
Veelen, A., Erazo‐Tapia, E., Oscarsson, J., & Schrauwen, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101158 · Cited by 50
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
Dąbrowski, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041680 · Cited by 50
Adipose Tissue-Endothelial Cell Interactions in Obesity-Induced Endothelial Dysfunction
Li, M., Qian, M., Kyler, K., & Xu, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.681581 · Cited by 50
Nakao, M., Shimizu, I., Katsuumi, G., Yoshida, Y., Suda, M., Hayashi, Y., Ikegami, R., Hsiao, Y., Okuda, S., Soga, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97787-2 · Cited by 48
Tian, Q., Guo, K., Deng, J., Zhong, Y., & Yang, L. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17115 · Cited by 51
Hypertension in Patients with Insulin Resistance: Etiopathogenesis and Management in Children
Tagi, V. M., Mainieri, F., & Chiarelli, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105814 · Cited by 48
Mori, Y., Duru, O. K., Tuttle, K. R., Fukuma, S., Taura, D., Harada, N., Inagaki, N., & Inoue, K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac591 · Cited by 48
Diabetic cardiomyopathy: The role of microRNAs and long non-coding RNAs
Mačvanin, M., Gluvic, Z. M., Radovanović, J., Essack, M., Gao, X., & Isenović, E. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1124613 · Cited by 47
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 55
Bidulka, P., Lugo-Palacios, D. G., Carroll, O., O’Neill, S., Adler, A., Basu, A., Silverwood, R. J., Bartlett, J. W., Nitsch, D., Charlton, P., et al. (2024) · BMJ · doi:10.1136/bmj-2023-077097 · Cited by 52
Martínez, J. J. G., Górriz, J. L., Cuenca, A. M. C., Conde, A. C., & Velasco, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216509 · Cited by 54
Cardiac Output and Renal Dysfunction
Müllens, W., & Nijst, P. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.537 · Cited by 47
Rahman, A., Hitomi, H., & Nishiyama, A. (2017) · Hypertension Research · doi:10.1038/hr.2016.193 · Cited by 47
CHILTON, R. J., Tikkanen, I. T., Hehnke, U., Woerle, H. J., & Johansen, O. E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12962 · Cited by 48
Self-citationHemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Sano, M. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3011w · Cited by 47
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., Bjornstad, P., Kramer, M. H. H., Diamant, M., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13223 · Cited by 49
The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)
Prat, L. I., & Tsochatzis, E. A. (2018) · HORMONES · doi:10.1007/s42000-018-0021-9 · Cited by 46
Dore, F. J., Domingues, C. C., Ahmadi, N., Kundu, N., Kropotova, Y., Houston, S., Rouphael, C., Mammadova, A., Witkin, L., Khiyami, A. M., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0709-9 · Cited by 49
Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care
Danne, T., Biester, T., & Kordonouri, O. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0081 · Cited by 48
MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update
Cao, Q., Chen, X., Huang, C., & Pollock, C. A. (2019) · FASEB BioAdvances · doi:10.1096/fba.2018-00064 · Cited by 48
Recent advances in diabetes treatments and their perioperative implications
Kuzulugil, D., Papeix, G., Luu, J., & Kerridge, R. K. (2019) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000735 · Cited by 49
Filion, K. B., Douros, A., Azoulay, L., Yin, H., Yu, O. H. Y., & Suissa, S. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14056 · Cited by 48
Nicolucci, A., Charbonnel, B. H., Gomes, M. B., Khunti, K., Kosiborod, M., Shestakova, M. V., Shimomura, I., Watada, H., Chen, H., Cid‐Ruzafa, J., et al. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13830 · Cited by 48
Chiang, H., Lee, J., Huang, H., Huang, H. Y., Liu, H., & Huang, C. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14859 · Cited by 48
Hampp, C., Swain, R. S., Horgan, C. E., Dee, E., Qiang, Y., Dutcher, S. K., Petrone, A. B., Tilney, R. C., Maro, J. C., & Panozzo, C. A. (2019) · Diabetes Care · doi:10.2337/dc19-1481 · Cited by 46
Yang, Y., Zhao, C., Ye, Y., Yu, M., & Qu, X. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00190 · Cited by 50
Sayour, A. A., Oláh, A., Ruppert, M., Barta, B. A., Horvath, E. M., Benke, K., Pólos, M., Hartyánszky, I. L., Merkely, B. P., & Radovits, T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01141-1 · Cited by 46
Reverse Cardiac Remodeling and ARNI Therapy
Abboud, A., & Januzzi, J. L. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00501-6 · Cited by 48
Bonilha, I., Zimetti, F., Zanotti, I., Papotti, B., & Sposito, A. C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112233 · Cited by 48
Srivastava, S. P., Zhou, H., Setia, O., Dardik, A., Fernandez-Hernando, C. F., & Goodwin, J. E. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019437 · Cited by 47
Lévy, S., Steinbeck, G., Santini, L., Näbauer, M., Penela, D., Kantharia, B. K., Saksena, S. V., & Cappato, R. (2022) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-022-01195-z · Cited by 50
Adam, C. A., Anghel, R. C., Marcu, D. T. M., Mitu, O., Roca, M., & Mitu, F. (2022) · Life · doi:10.3390/life12060803 · Cited by 49
DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Razavi, M. A., Wei, Y., Rao, X., & Zhong, J. (2022) · Military Medical Research · doi:10.1186/s40779-022-00410-2 · Cited by 50
Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis
Dixit, A. A., Bateman, B. T., Hawn, M. T., Odden, M. C., & Sun, E. C. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2024.7082 · Cited by 47
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw009 · Cited by 46
Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
García‐Ropero, Á., Vargas-Delgado, A. P., Santos‐Gallego, C. G., & Badimón, J. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133289 · Cited by 47
Kalra, D. K., Vijayaraghavan, K., Sikand, G., Desai, N. R., Joshi, P. H., Mehta, A., Karmally, W., Vani, A. K., Sitafalwalla, S. J., Puri, R., et al. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.03.007 · Cited by 50
Aktaa, S., Gencer, B., Arbelo, E., Davos, C. H., Désormais, I., Hollander, M., Abreu, A., Ambrosetti, M., Bäck, M., Carballo, D., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab160 · Cited by 52
Pruett, J. E., Everman, S. J., Hoang, N., Salau, F., Taylor, L. C., Edwards, K. S., Hosler, J. P., Huffman, A. M., Romero, D. G., & Cardozo, L. L. Y. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00455-x · Cited by 46
Werbner, B., Tavakoli‐Rouzbehani, O. M., Fatahian, A. N., & Boudina, S. (2023) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2022.42 · Cited by 44
SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
Podestà, M. A., Sabiu, G., Galassi, A., Ciceri, P., & Cozzolino, M. G. (2023) · Biomedicines · doi:10.3390/biomedicines11020279 · Cited by 47
Dimitriadis, K. S., Adamopoulou, E., Pyrpyris, N., Sakalidis, A., Leontsinis, I., Manta, E., Mantzouranis, E., Beneki, E., Σουλαϊδόπουλος, Σ., Konstantinidis, D., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad053 · Cited by 50
SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
Mariani, M. V., Manzi, G., Pierucci, N., Laviola, D., Piro, A., D’Amato, A., Filomena, D., Matteucci, A., Severino, P., Miraldi, F., et al. (2024) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16344 · Cited by 48
Salsali, A., Kim, G.-H., Woerle, H. J., Broedl, U. C., & Hantel, S. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12734 · Cited by 46
Self-citationTanabe, M., Motonaga, R., Terawaki, Y., Nomiyama, T., & Yanase, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12567 · Cited by 45
Gholap, N. N., Achana, F. A., Davies, M. J., Ray, K. K., Gray, L. J., & Khunti, K. K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12827 · Cited by 45
Yoshikawa, T., Kishi, T., Shinohara, K., Takesue, K., Shibata, R., Sonoda, N., Inoguchi, T., Sunagawa, K., Tsutsui, H., & Hirooka, Y. (2017) · Hypertension Research · doi:10.1038/hr.2017.14 · Cited by 47
Lessons Learned in Acute Heart Failure
Cheema, B. S., Ambrosy, A. P., Kaplan, R. M., Senni, M., Fonarow, G. C., Chioncel, O. D., Butler, J., & Gheorghiade, M. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.1042 · Cited by 47
SGLT2 inhibitors and the kidney: Effects and mechanisms
Tsimihodimos, V., Filippatos, T. D., & Elisaf, M. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.06.003 · Cited by 48
Empagliflozin, Calcium, and SGLT1/2 Receptor Affinity: Another Piece of the Puzzle
Anker, S. D., & Butler, J. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12345 · Cited by 46
on behalf of the Scottish Diabetes Research Network Epidemiology Group, McGurnaghan, S. J., Brierley, L., Caparrotta, T. M., McKeigue, P. M., Blackbourn, L. A. K., Wild, S. H., Leese, G. P., McCrimmon, R. J., McKnight, J. A., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4806-9 · Cited by 46
Phrommintikul, A., Wongcharoen, W., Kumfu, S., Jaiwongkam, T., Gunaparn, S., Chattipakorn, S. C., & Chattipakorn, N. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13903 · Cited by 48
Seo, D. Y., Ko, J. R., Jang, J. E., Kim, T. N., Youm, J. B., Kwak, H., Bae, J. H., Kim, A. H., Ko, K. S., Rhee, B. D., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246284 · Cited by 46
Himeno, T., Kamiya, H., & Nakamura, J. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13173 · Cited by 49
Verma, S., Ji, Q., Bhatt, D. L., Mazer, C. D., Al-Omran, M. A., Inzucchi, S. E., Wanner, C., Ofstad, A. P., Zwiener, I., George, J. T., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13991 · Cited by 46
Self-citationHeart failure management in dialysis patients: Many treatment options with no clear evidence
Roehm, B. A., Gulati, G., & Weiner, D. E. (2020) · Seminars in Dialysis · doi:10.1111/sdi.12878 · Cited by 46
Inzucchi, S. E., Khunti, K., FITCHETT, D. H., Wanner, C., Mattheus, M., George, J. T., Ofstad, A. P., & Zinman, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa321 · Cited by 47
Self-citationHaye, A., Ansari, M. A., Rahman, S. O., Shamsi, Y., Ahmed, D., & Sharma, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173376 · Cited by 47
Loss of Mitochondrial Control Impacts Renal Health
Srivastava, S. P., Kanasaki, K., & Goodwin, J. E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.543973 · Cited by 48
Becher, P. M., Schrage, B., Ferrannini, G., Benson, L., Butler, J., Carrero, J. J., Cosentino, F., Dahlström, U., Mellbin, L., Rosano, G. M. C., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2131 · Cited by 46
Verbrugge, F. H., Reddy, Y. N. V., Sorimachi, H., Omote, K., Carter, R. E., & Borlaug, B. A. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2142 · Cited by 49
Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice
Liu, Y., Wu, M., Xu, J., Xu, B., & Kang, L. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105788 · Cited by 47
Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia
Azam, M. A., Chakraborty, P., Si, D., Du, B., Massé, S., Lai, P. F. H., Ha, A. C. T., & Nanthakumar, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119440 · Cited by 49
Liu, H., Sridhar, V. S., Lovblom, L. E., Lytvyn, Y., Burger, D. E., Burns, K. D., Brinc, D., Lawler, P. R., & Cherney, D. Z. I. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.022 · Cited by 46
Sánchez, J. J. G., Thompson, J. C., Scott, D. A., Evans, R., Rao, N., Sörstadius, E., James, G., NOLAN, S. T., Wittbrodt, E. T., Sultan, A. A., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-02006-z · Cited by 53
Metadata
- Authors
- Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E.
- Affiliations
- Mount Sinai Hospital (CA)
- University of Würzburg (DE)
- George Washington University (US)
- University of Toronto (CA)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (United States) (US)
- Boehringer Ingelheim (Norway) (NO)
- Yale University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2117-2128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2146264128
- Semantic Scholar
- b43c548120609d766a5fec5a495baa81903ab3f2
- Cited by
- 12,315
- References
- 28
- Citations by year
- 2026: 741 · 2025: 1017 · 2024: 1082 · 2023: 1131 · 2022: 1300 · 2021: 1451 · 2020: 1380 · 2019: 1206 · 2018: 1069 · 2017: 948 · 2016: 688 · 2015: 87
- FWCI
- 567.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- empagliflozin, SGLT2 inhibitors, type 2 diabetes, cardiovascular outcomes, cardiovascular mortality, heart failure hospitalization, myocardial infarction, stroke
- MeSH terms
- Aged, Benzhydryl Compounds, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
